1. Articles in category: Disease Classification

    1-24 of 111 1 2 3 4 5 »
    1. Elevated Preoperative Neutrophil-Lymphocyte Ratio is Predictive of a Poorer Prognosis for Pediatric Patients with Solid Tumors.

      Elevated Preoperative Neutrophil-Lymphocyte Ratio is Predictive of a Poorer Prognosis for Pediatric Patients with Solid Tumors.

      Ann Surg Oncol. 2017 Jul 17;:

      Authors: Nayak A, McDowell DT, Kellie SJ, Karpelowsky J

      Abstract BACKGROUND: An elevated neutrophil-lymphocyte ratio (NLR) has been shown to indicate poorer prognosis for adults with solid tumors and potentially represents an independent, universal adjunct prognostic factor.

      Read Full Article
    2. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Proc Natl Acad Sci U S A. 2017 Jul 10;:

      Authors: Westerlund I, Shi Y, Toskas K, Fell SM, Li S, Surova O, Södersten E, Kogner P, Nyman U, Schlisio S, Holmberg J

      Read Full Article
      Mentions: Treatment MYCN
    3. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

      Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

      Cancer. 2017 Jul 11;:

      Authors: Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG

      Read Full Article
      Mentions: Staging COG MYCN
    4. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors.

      Metabolic syndrome induced by anticancer treatment in childhood cancer survivors.

      Ann Pediatr Endocrinol Metab. 2017 Jun;22(2):82-89

      Authors: Chueh HW, Yoo JH

      Abstract The number of childhood cancer survivors is increasing as survival rates improve. However, complications after treatment have not received much attention, particularly metabolic syndrome.

      Read Full Article
      Mentions: Treatment
    5. Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

      Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jul 07;:

      Authors: Stone A, Novetsky Friedman D, Worgall S, Kushner BH, Wolden S, Modak S, LaQuaglia MP, Wu X, Cheung NK, Sklar CA

      Abstract BACKGROUND: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities.

      Read Full Article
    6. Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      J Pediatr Hematol Oncol. 2017 Jul 03;:

      Authors: Ari P, Kars M, Meany H, Pestieau S

      Abstract Children with high-risk neuroblastoma are currently treated with a chimeric monoclonal antibody against GD2 ganglioside (chimeric 14.18). The treatment improves survival but causes transient neuropathic pain-like syndrome.

      Read Full Article
      Mentions: Antibody Treatment
    7. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Pediatr Hematol Oncol. 2017 Jun 29;:1-21

      Authors: Ahmed AA, Zhang L, Reddivalla N, Hetherington M

      Abstract Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8-10% of all childhood malignancies. The tumor is characterized by a spectrum of histopathologic features and a heterogeneous clinical phenotype.

      Read Full Article
      Mentions: MYCN
    8. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    9. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    10. Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

      Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

      Oncotarget. 2017 May 23;:

      Authors: Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A

      Read Full Article
      Mentions: ALK
    11. Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      MEMPHIS, Tenn., June 2, 2017 /PRNewswire/ -- Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CC...

      Read Full Article
      Mentions: Treatment
    12. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      J Pediatr Hematol Oncol. 2017 May 23;:

      Authors: Armstrong AE, Danner-Koptik K, Golden S, Schneiderman J, Kletzel M, Reichek J, Gosiengfiao Y

      Read Full Article
      Mentions: Chemotherapy
    13. Neuroblastoma Presenting as Non-MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by Fdg PET/CT Imaging.

      Neuroblastoma Presenting as Non-MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by FDG PET/CT Imaging.

      Clin Nucl Med. 2017 May 19;:

      Authors: Tolboom N, Servaes SE, Zhuang H

      Abstract Soft tissue metastases from neuroblastoma very rarely occur without concurrent osseous metastases. We report 1 case of non-MIBG-avid, high-risk neuroblastoma in a pediatric patient who had widespread soft tissue metastases without concurrent osseous lesion on FDG PET/CT imaging.

      Read Full Article
      Mentions: Imaging MIBG
    14. Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.

      "Incorporation of high-dose 131I-MIBG treatment into tandem HDCT/auto-SCT could reduce short- and long-term toxicities associated with TBI, without jeopardizing the survival rate."

      Read Full Article
    15. Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.

      Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.

      Neurosci Lett. 2017 May 12;:

      Authors: Hegarty SV, Togher KL, O'Leary E, Solger F, Sullivan AM, O'Keeffe GW

      Abstract Neuroblastoma is the most common extracranial pediatric solid tumor, arising from the embryonic sympathoadrenal lineage of the neural crest, and is responsible for 15% of childhood cancer deaths.

      Read Full Article
      Mentions: Treatment MYCN
    16. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Phase III

      Treatment

      Not yet active

      365 days to 30 years

      ANBL1531

      NCI-2016-01734, NCT03126916

      This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells.

      Read Full Article
      Mentions: Treatment INRG ALK
    17. High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis.

      Case Rep Pediatr. 2017;2017:5375091

      Authors: Yoshikawa T, Tanizawa A, Suzuki K, Ikeda K, Nomura E, Maeda Y, Tanaka N, Yamada K, Sakai Y, Imamura Y, Ohshima Y

      Abstract Renal metastasis at diagnosis with neuroblastoma is rare. We present a 14-month-old boy who was diagnosed with high-risk neuroblastoma with multiple metastases, including bilateral kidneys.

      Read Full Article
      Mentions: Metastasis
    18. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.

      TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Apr 27;:

      Authors: Duan XF, Zhao Q

      Abstract Neuroblastomas (NB) are one of the most common extracranial solid tumors in children, and they frequently display high heterogeneity in the disease course. With ongoing research, more information regarding the genetic etiology and molecular mechanisms underlying these contrasting phenotypes is being uncovered.

      Read Full Article
      Mentions: MYCN ATRX
    19. HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population.

      HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population.

      Onco Targets Ther. 2017;10:1969-1975

      Authors: Zhang Z, Zou Y, Zhu J, Zhang R, Yang T, Wang F, Xia H, He J, Feng Z

      Abstract A previous genome-wide association study (GWAS) identified four genetic polymorphisms (rs1027702 near DUSP12, rs10055201 in IL31RA, rs2619046 in DDX4, and rs11037575 in HSD17B12 gene) that were associated with neuroblastoma susceptibility, especially for low-risk subjects. The aim of this study was to examine the association between these four polymorphisms and neuroblastoma susceptibility in a Southern Chinese population composed of 256 cases ...

      Read Full Article
    20. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2017 Apr 24;:

      Authors: Mody R, Zhao L, Yanik GA, Opipari V

      Abstract PURPOSE: Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Read Full Article
    21. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes

      To evaluate the impact of image-defined risk factor (IDRF) modification after chemotherapy on surgical outcomes, event-free survival (EFS), and overall survival (OS) among patients enrolled in the European Unresectable Neuroblastoma (EUNB) study.

      IDRFs were assigned according to the corresponding surgical risk factors list reported in the database. Surgical outcomes, EFS, and OS were related to IDRF modification with chemotherapy.

      Read Full Article
      Mentions: SIOPEN Chemotherapy
    1-24 of 111 1 2 3 4 5 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) COG
  4. Researches in the News

    1. (3 articles) MYCN
    2. (1 articles) Antibody
  5. General Informations in the News

    1. (3 articles) Treatment
    2. (1 articles) Staging